WallStreetZenWallStreetZen

NASDAQ: AGRX
Agile Therapeutics Inc Earnings & Revenue

Open Broker Account

AGRX past revenue growth

How has AGRX's revenue growth performed historically?
Company
226.24%
Industry
231.18%
Market
114.96%
AGRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AGRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AGRX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AGRX earnings and revenue history

Current Revenue
$6.7M
Current Earnings
-$64.1M
Current Profit Margin
-958.7%

AGRX Return on Equity

Current Company
-982.1%
Current Industry
15.1%
Current Market
25.7%
AGRX's Return on Equity (-982.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when AGRX announces earnings.

AGRX Return on Assets

Current Company
-185.7%
Current Industry
4%
AGRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AGRX Return on Capital Employed

Current Company
-1,607.76%
Current Industry
8.6%
AGRX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AGRX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AGRX$6.69M-$62.79M-$64.12M+226.24%N/A
PTPI$7.93M-$4.84M-$11.87M-38.66%N/A
NEPT$56.09M-$54.03M-$63.33M+29.88%N/A
HAPP$89.49M-$50.64M-$49.19M+11.05%N/A
GHSI$11.44M-$20.53M-$21.86M+124.97%N/A

AGRX earnings dates

Next earnings date
Oct 31, 2022

Agile Therapeutics Earnings & Revenue FAQ

What were AGRX's earnings last quarter?

On Invalid Date, Agile Therapeutics (NASDAQ: AGRX) reported Q2 2022 earnings per share (EPS) of -$2.71, up 66.13% year over year. Total Agile Therapeutics earnings for the quarter were -$12.22 million. In the same quarter last year, Agile Therapeutics's earnings per share (EPS) was -$8.00.

If you're new to stock investing, here's how to buy Agile Therapeutics stock.

What was AGRX's earnings growth in the past year?

As of Q4 2022, Agile Therapeutics's earnings has grown year over year. Agile Therapeutics's earnings in the past year totalled -$64.12 million.

What is AGRX's earnings date?

Agile Therapeutics's earnings date is Invalid Date. Add AGRX to your watchlist to be reminded of AGRX's next earnings announcement.

What was AGRX's revenue last quarter?

On Invalid Date, Agile Therapeutics (NASDAQ: AGRX) reported Q2 2022 revenue of $2.13 million up 79.41% year over year. In the same quarter last year, Agile Therapeutics's revenue was $1.19 million.

What was AGRX's revenue growth in the past year?

As of Q4 2022, Agile Therapeutics's revenue has grown 226.24% year over year. This is 4.93 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 231.18%. Agile Therapeutics's revenue in the past year totalled $6.69 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.